**Visual outcome and treatment frequency of anti-VEGF therapy using the treat-and-extend and treatment cessation regimen for exudative age-related macular degeneration and pachychoroid neovasculopathy**

**Clinical Ophthalmology**

Takamasa Kinoshita, MD, PhD; Junya Mori, MD; Akira Hatanaka, MD; Miho Shimizu, MD; Hiroko Imaizumi, MD, PhD

Correspondence: Takamasa Kinoshita, MD, PhD. Department of Ophthalmology, Sapporo City General Hospital, 1-1, N-11, W-13, Chuoku, Sapporo, 060-8604, Japan

E-mail: knst129@gmail.com

Table S1: Reasons for exclusion from the study and discontinuation of visits after year 1

|  |  |  |  |
| --- | --- | --- | --- |
| Reason for exclusion (duplicated) | n | Reason for discontinuation after year 1 | n |
| Previous anti-VEGF therapy and/or PDT | 29 | Continued to be followed-up by other local physicians | 16 |
| Fellow eyes were included | 17 | Hospitalization | 7 |
| Treated with PRN by patients preferences | 4 | Lost to follow-up | 5 |
| Subfoveal scarring at baseline | 3 | Progressive dementia | 2 |
| Treatment discontinuation by patients before year 1 | 2 | Death | 1 |
| Lost to follow-up before year 1 | 2 | Other | 1 |
| Total | 39 |  | 32 |

VEGF, vascular endothelial growth factor; PDT, photodynamic therapy; PRN, pro re nata.